Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma - Quiz - MDSpire

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

  • By

  • Luisina María Solernó

  • Candela Llavona

  • Zahira Yasmine Saud

  • Mariana Carolina Onassis

  • María Florencia Gottardo

  • Martín Manuel Ledesma

  • Daniel Fernando Alonso

  • Juan Garona

  • July 1, 2026

  • 0 min

Share

Original Source(s)

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

  • by Luisina María Solernó, Candela Llavona, Zahira Yasmine Saud, Mariana Carolina Onassis, María Florencia Gottardo, Martín Manuel Ledesma, Daniel Fernando Alonso, Juan Garona

  • July 1, 2026

Related Content

Predicting overall survival in synchronous metastatic nasopharyngeal carcinoma using a stacking ensemble machine learning model: a multicenter retrospective study

Case report: A case of adolescent invasive encapsulated follicular variant of papillary thyroid carcinoma with literature review

Systematic pan-cancer analysis reveals context-dependent prognostic and immunological roles of WDR1 with divergent effects in renal and gastric cancers